Feeds:
Posts
Comments

Archive for the ‘Variation in human protein-coding regions’ Category

New subgroups of ILC immune cells discovered through single-cell RNA sequencing

Reporter: Stephen J Williams, PhD

 

UPDATED on 8/8/2020

A Hybrid Deep Clustering Approach for Robust Cell Type Profiling Using Single-cell RNA-seq Data

  1. Suhas Srinivasan1,
  2. Anastasia Leshchyk1,
  3. Nathan J Johnson2 and
  4. Dmitry Korkin1,3

+Author Affiliations

  1. 1 Worcester Polytechnic Institute;
  2. 2 Harvard Medical School and Dana Farber Cancer Institute
  1. * Corresponding author; email: korkin@korkinlab.org

Abstract

Single-cell RNA sequencing (scRNA-seq) is a recent technology that enables fine-grained discovery of cellular subtypes and specific cell states. It routinely uses machine learning methods, such as feature learning, clustering, and classification, to assist in uncovering novel information from scRNA-seq data. However, current methods are not well suited to deal with the substantial amounts of noise that is created by the experiments or the variation that occurs due to differences in the cells of the same type. Here, we develop a new hybrid approach, Deep Unsupervised Single-cell Clustering (DUSC), that integrates feature generation based on a deep learning architecture with a model-based clustering algorithm, to find a compact and informative representation of the single-cell transcriptomic data generating robust clusters. We also include a technique to estimate an efficient number of latent features in the deep learning model. Our method outperforms both classical and state-of-the-art feature learning and clustering methods, approaching the accuracy of supervised learning. We applied DUSC to single-cell transcriptomics dataset obtained from a triple-negative breast cancer tumor to identify potential cancer subclones accentuated by copy-number variation and investigate the role of clonal heterogeneity. Our method is freely available to the community and will hopefully facilitate our understanding of the cellular atlas of living organisms as well as provide the means to improve patient diagnostics and treatment.

Keywords

  • Received January 3, 2020.
  • Accepted May 22, 2020.

This article is distributed exclusively by the RNA Society for the first 12 months after the full-issue publication date (see http://rnajournal.cshlp.org/site/misc/terms.xhtml). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at http://creativecommons.org/licenses/by-nc/4.0/.

 

New subgroups of ILC immune cells discovered through single-cell RNA sequencing

SOURCE

http://ki.se/en/news/new-subgroups-of-ilc-immune-cells-discovered-through-single-cell-rna-sequencing?elqTrackId=f79885cef36049e281109c02da213910&elq=ac700a4d4374478b9d6e10e301ae6b90&elqaid=14707&elqat=1&elqCampaignId=14

Updated on 2016-02-15. Published on 2016-02-15Denna sida på svenska

Jenny Mjösberg and Rickard Sandberg are principal investigators at Karolinska Institutet’s Department of Medicine, Huddinge and Department of Cell and Molecular Biology, respectively. Credit: Stefan Zimmerman.

A relatively newly discovered group of immune cells known as ILCs have been examined in detail in a new study published in the journal Nature Immunology. By analysing the gene expression in individual tonsil cells, scientists at Karolinska Institutet have found three previously unknown subgroups of ILCs, and revealed more about how these cells function in the human body.

Innate lymphoid cells (ILCs) are a group of immune cells that have only relatively recently been discovered in humans. Most of current knowledge about ILCs stems from animal studies of e.g. inflammation or infection in the gastrointestinal tract. There is therefore an urgent need to learn more about these cells in humans.

Previous studies have shown that ILCs are important for maintaining the barrier function of the mucosa, which serves as a first line of defence against microorganisms in the lungs, intestines and elsewhere. However, while there is growing evidence to suggest that ILCs are involved in diseases such as inflammatory bowel disease, asthma and intestinal cancer, basic research still needs to be done to ascertain exactly what part they play.

Two research groups, led by Rickard Sandberg and Jenny Mjösberg, collaborated on a study of ILCs from human tonsils. To date, three main groups of human ILCs are characterized. In this present study, the teams used a novel approach that enabled them to sort individual tonsil cells and measure their expression across thousands of  genes. This way, the researchers managed to categorise hundreds of cells, one by one, to define the types of ILCs found in the human tonsils.

Unique gene expression profiles

Rickard Sandberg, credit: Stefan Zimmerman,

“We used cluster analyses to demonstrate that ILCs congregate into ILC1, ILC2, ILC3 and NK cells, based on their unique gene expression profiles,” says Professor Sandberg at Karolinska Institutet’sDepartment of Cell and Molecular Biology, and the Stockholm branch of Ludwig Cancer Research. “Our analyses also discovered the expression of numerous genes of previously unknown function in ILCs, highlighting that these cells are likely doing more than what we previously knew.”

By analysing the gene expression profiles (or transcriptome) of individual cells, the researchers found that one of the formerly known main groups could be subdivided.

Jenny Mjösberg, credit: Stefan Zimmerman.

“We’ve identified three new subgroups of ILC3s that evince different gene expression patterns and that differ in how they react to signalling molecules and in their ability to secrete proteins,” says Dr Mjösberg at Karolinska Institutet’s Department of Medicine in Huddinge, South Stockholm. “All in all, our study has taught us a lot about this relatively uncharacterised family of cells and our data will serve as an important resource for other researchers.”

The study was financed by grants from a number of bodies, including the Swedish Research Council, the Swedish Cancer Society, the EU Framework Programme for Research and Innovation, the Swedish Society for Medical Research, the Swedish Foundation for Strategic Research and Karolinska Institutet.

Publication

The heterogeneity of human CD127+ innate lymphoid cells revealed by single-cell RNA sequencing
Åsa K. Björklund, Marianne Forkel, Simone Picelli, Viktoria Konya, Jakob Theorell, Danielle Friberg, Rickard Sandberg, Jenny Mjösberg
Nature Immunology, online 15 February 2016, doi:10.1038/ni.3368

Read Full Post »

A newly described method linearizes circular chromosomes and caps them with telomeres

Reporter: Aviva Lev-Ari, PhD, RN

 

 

Synthetic biologists often work with circular chromosomes to engineer genetic material because they’re stable and easy to manipulate, but they don’t resemble the natural shape of chromosomes in eukaryotes. Reporting in PNAS this week (November 5), Jef Boeke of NYU Langone Medical Center and postdoc Leslie Mitchell designed a tool, which they dubbed the telomerator, that straightens circular yeast chromosomes and adds telomeres to either end.

 

“To convert circular DNA to something more akin to a natural chromosome is appealing,” said Timothy Lu, a synthetic biologist at MIT who was not involved in the study. Lu said the telomerator could help advance a number of goals, from designing artificial chromosomes that encode complex pathways to testing the significance of telomere location in the genome. “It’s really a platform technology for downstream applications.”

 

The telomerator includes an endonuclease target—the site where the DNA loop will be severed—flanked by telomere seed sequences that form the basis of telomere construction. The telomerator is inserted into a gene of interest in the circular chromosomes, and when an endonuclease cuts the sequence at the recognition site, each exposed end carries a seed sequence on which to build telomeres. “The reason you can actually linearize the molecule and produce a stable molecule is because this telomere seed sequence gets exposed,” explained Mitchell. She and Boeke engineered the telomerator so that it would be induced only in the presence of galactose, giving scientists an easy way to turn it on by simply changing the growth medium.

 

The researchers tested the telomerator on a synthetic chromosome designed a few years earlier, cutting it at 54 different genes. For 51 of the permutations, “we got pretty happy yeast at the end of the experiment,” said Boeke. For another three, it appeared that the proximity of essential genes to the new telomere interfered with their expression, a phenomenon known as telomeric silencing. Blocking telomeric silencing rescued the cells’ growth. “I would say we’ve worked out most of the kinks for yeast,” said Boeke. “All you need to decide right now is where you want to put it.”

 

Yo Suzuki, a synthetic biologist at the J. Craig Venter Institute, said that linearizing DNA is important to avoiding problems in meiotic recombination that can emerge with circular chromosomes. In particular, crossover events between two circular chromosomes can result in a chromosome with two centromeres, which would break during chromosome segregation. “If you have a linear molecule in yeast, you don’t have that problem,” Suzuki said.

Source: www.the-scientist.com

See on Scoop.itCardiovascular and vascular imaging

Read Full Post »

All Ashkenazi Jews alive today can trace their roots to a group of just 350 people who lived 600 to 800 years ago

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

 

 

 

 

 

 

 

 

Ashkenazi Jews (AJ), identified as Jewish individuals of Central- and Eastern European ancestry, form the largest genetic isolate in the United States. AJ demonstrate distinctive genetic characteristics1, 2, including high prevalence of autosomal recessive diseases and relatively high frequency of alleles that confer a strong risk of common diseases, such as Parkinson’s disease3and breast and ovarian cancer4. Several recent studies have employed common polymorphisms5,-13 to characterize AJ as a genetically distinct population, close to other Jewish populations as well as to present-day Middle Eastern and European populations. Previous analyses of recent AJ history highlighted a narrow population bottleneck of only hundreds of individuals in late medieval times, followed by rapid expansion12, 14.

 

The AJ population is much larger and/or experienced a more severe bottleneck than other founder populations, such as Amish, Hutterites or Icelanders15, whose demographic histories facilitated a steady stream of genetic discoveries. This suggests the potential for cataloguing nearly all founder variants in a large extant population by sequencing a limited number of samples, who represent the diversity in the founding group (for example, ref. 16). Such a catalogue of variants can make a threefold contribution: First, it will enable clinical interpretation of personal genomes in the sizeable AJ population by distinguishing between background variation and recent, potentially more deleterious mutations. Second, it will improve disease mapping in AJ by increasing the accuracy of imputation. Third, the ability to extensively sample a population with ancient roots in the Levant is expected to provide insights regarding the histories of both Middle Eastern and European populations.

 

Now a team of scientists report high-depth sequencing of 128 complete genomes of AJ controls. Compared with European samples, our AJ panel has 47% more novel variants per genome and is eightfold more effective at filtering benign variants out of AJ clinical genomes. Reconstruction of recent AJ history from such data confirms a recent bottleneck of merely ≈350 individuals. Modeling of ancient histories for AJ and European populations using their joint allele frequency spectrum determines AJ to be an even admixture of European and likely Middle Eastern origins. The researchers date the split between the two ancestral populations to ≈12–25 Kyr, suggesting a predominantly Near Eastern source for the repopulation of Europe after the Last Glacial Maximum.

Source: www.nature.com

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Keep, Delete, Modify: Synthetic Genes, Synthetic Cells, Synthetic Life

Reporter: Aviva Lev-Ari, PhD, RN

 

Nature needed about one billion years to create the simplest single-cell organisms that swam around in the primordial soup. Now, scientists are eager to create synthetic life – but better and faster.

 

Hamilton Smith (Nobel Prize in Chemistry 1978 with Werner Arber and Daniel Nathans) started his lecture at the 64th Nobel Laureate Meeting in Lindau with a quote from Richard Feynman (Nobel Prize in Physics 1965): Feynman had probably meant physical models, whereas Smith referred to living organisms. In his laboratory at the J. Craig Venter Institute, he tries to create synthetic cells: “I hope that if we create that, we will understand.”

 

Nowadays, the entire human genome has been decoded. But how a live human being develops from DNA molecules, a human being that can breath, eat, walk, study, love, receive Nobel Prizes and award them – nobody really understands yet. Even for single-cell organisms, this isn’t crystal clear. Even the simplest bacteria exhibit genes without apparent function, that are not essential for life. During evolution, a lot of ‘genetic waste’ has accumulated that might have been useful at some point, but was rendered useless by mutations. Some genetic fragments were in fact smuggled into the genome by viruses, others were created by accidental duplications of genetic segments. Numerous molecular mechanisms lead to many genetic variations – rendering evolution possible in the first place. But over time, many of these genes and segments have become useless.

 

Currently Smith tries to tidy up the genome of Mycoplasma mycoides, a microbe normally living in the digestive tract of ruminants. Originally Smith and his team wanted to use the genome of Mycoplasma genitalium, the bacterium with the smallest known genome – it needs only 475 genes to live. Smith estimates that about 100 of these are non-essential. But since M. mycoides has a much higher cell division rate, although its genome is twice as large, experiments with M. mycoides proved to be more effective. During this ‘minimal cell project’, the researchers switch off one gene after another and study the effects on the microbes. (And the slower the microbes grow, the longer the researchers have to wait for their results.) Smith’s final goal is “a genome that is very understandable – we are searching for the genetic kernels of life”.

 

Smith also assumes that all genes from the last group can be switched off without negative impacts on the microbes. Concerning the middle category, the researchers have to carefully weigh all options. When all is done, the result should be a bacterium that can still multiply rapidly, at least in laboratory conditions that offer plenty of nourishment, constant temperatures, but no competitors. The researchers’ goal is a fifty percent genome reduction in a happily thriving microbe that divides at least once in 100 minutes.

 

Smith likes using computer terms to describe his work. He compares the genome of any organism with its software, the rest is hardware (the cytoplasm, proteins and enzymes), controlled by said software. As soon as a cell receives a new genetic program, it starts to put this program to use. In order to test their own synthetic programs, Smith and his team replaced the bacterium’s DNA with synthetic DNA containing their basic program. To date, the old ‘hardware’ has not adopted the new program ‘update’. In computer speak, troubleshooting and maintenance are called “debugging”: Smith and his team will be busy with debugging for some time.

 

Source: blog.lindau-nobel.org

See on Scoop.itCardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

Ca Prevention: Calcium May Protect Colon

Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco

WASHINGTON — Increasing calcium intake may lower the risk of colorectal adenomas in people who are at increased risk of the precancerous lesions due to variations in two genes, researchers reported here.

In a two-phase, case-control study of nearly 6,000 subjects, high calcium intake was associated with a significantly reduced risk of adenoma among those who carried variants in the KCNJ and SLC12A1 genes.

High calcium intake was not associated with a reduced risk of colorectal adenoma among those with no variants in KCNJ and SLC12A1, both of which are essential to calcium reabsorption in the kidney, reported Xiangzhu Zhu, MD, of Vanderbilt-Ingram Cancer Center at the American Association for Cancer Research meeting here.

The two-phase study was undertaken to explore whether 14 genes involved in calcium homeostasis are associated with the risk for colorectal adenoma. The researchers also wanted to determine whether intake of calcium and magnesium modified any such risks.

To do so, they utilized data from 1,818 cases and 3,992 controls enrolled in the Tennessee Colorectal Polyp Study. Of the 14 genes,KCNJ and SLC12A1 were found to modify the risk between calcium intake and adenomas.

Among the findings:

  • 52% of participants had a variant allele in one of the two genes, and 13% carried variant alleles in both genes.
  • In people with both gene variants, those the top tertile of calcium intake – consuming 1,300 mg a day or more – had a 69% lower risk of adenoma than people in the lowest tertile, who consumed less than 1,000 mg a day (for trend=0.039).
  • In patients who had one gene variant, there was a 39% reduction in adenomas for those in the highest tertile compared with those in the lowest tertile (for trend=0.046).

The risk for advanced or multiple adenomas were reduced by 89% among those with variants in both genes (for trend=.01).

If confirmed, the findings suggest that patients who carry one or both variants should increase their calcium intake to at least 1,300 mg per day, either through diet or supplementation, Zhu said.

The findings may also “provide one possible explanation for the inconsistency in previous studies on calcium intake and colorectal abnormalities,” she said.

Further study will be needed to confirm the findings, commented Susan T. Mayne, PhD, of Yale University School of Public Health.

Mayne said the study emphasizes that “one size does not always fit all” when it comes to optimal nutrient intakes.

James R. Marshall, PhD, senior vice president of cancer prevention and population sciences at Roswell Park Cancer Institute in Buffalo, N.Y., agreed, pointing out that studies like this are needed to find biomarkers that can pinpoint those patients most likely to benefit from prevention strategies.

“Case-control studies raise possibilities that help to define which patients to include in future trials,” Marshall said.

Kathleen Struck, MedPage Today Senior Editor, contributed to this article.

The possibility that a supplement such as calcium may prove to be a useful chemoprevention agent is intriguing, but a single study is just a single study — worthy of more investigation. Share your thoughts and read what your colleagues are saying about calcium and colon cancer by clicking the Add Your Knowledge link at the bottom of this article. — Sanjay Gupta, MD

The authors reported no relevant financial disclosures.

Mayne and Marshall reported no relevant financial disclosures.

Primary source: American Association for Cancer Research

Read Full Post »

« Newer Posts